Page 46 - 2021_12-Haematologica-web

L. Zalmai et al.
Haematol. 2009;145(5):624-636.
7. Facchetti F, Cigognetti M, Fisogni S, Rossi G,
Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-111.
8. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. Lyon, France: International Agency for Research on Cancer; 2017.
9. Petrella T, Comeau MR, Maynadié M, et al. “Agranular CD4+ CD56+ hematodermic neoplasm” (blastic NK-cell lymphoma) orig- inates from a population of CD56+ precur- sor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26(7):852-862.
10.Petrella T, Facchetti F. Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009? Autoimmunity. 2010; 43(3):210-214.
11. Vitte F, Fabiani B, Bénet C, et al. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012;36(9):1302- 1316.
12. Dargent J-L, Delannoy A, Pieron P, Husson B, Debecker C, Petrella T. Cutaneous accu- mulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasma- cytoid dendritic cell neoplasm. J Cutan Pathol. 2011;38(11):893-898.
13. Orazi A, Chiu R, O’Malley DP, et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol. 2006;19(12):1536-1545.
14. Hamadeh F, Awadallah A, Meyerson HJ, Beck RC. Flow cytometry identifies a spec- trum of maturation in myeloid neoplasms having plasmacytoid dendritic cell differen- tiation. Cytometry B Clin Cytom. 2020; 98(1):43-51.
15. Huang Y, Wang Y, Chang Y, et al. Myeloid neoplasms with elevated plasmacytoid den- dritic cell differentiation reflect the matura- tion process of dendritic cells. Cytom A. 2020;97(1):61-69.
16. Wang P, Feng Y, Deng X, et al. Tumor-form- ing plasmacytoid dendritic cells in acute myelocytic leukemia: a report of three cases and literature review. Int J Clin Exp Pathol. 2017;10(7):7285-7291.
17. Xiao W, Goldberg AD, Famulare C, et al. Acute myeloid leukemia with plasmacytoid dendritic cell differentiation: predominantly Secondary AML, enriched for RUNX1 mutations, frequent cross-lineage antigen expression and poor prognosis. Blood. 2018;132(Suppl 1):S2789.
18. Bodmer A, Menter T, Juskevicius D, et al. Sharing of a PTPN11 mutation by myelodysplastic bone marrow and a mature plasmacytoid dendritic cell proliferation pro- vides evidence for their common myelomonocytic origin. Virchows Arch. 2017;470(4):469-473.
19. Horny HP, Feller AC, Horst HA, Lennert K. Immunocytology of plasmacytoid T cells: marker analysis indicates a unique pheno- type of this enigmatic cell. Hum Pathol. 1987;18(1):28-32.
20. Angelot-Delettre F, Biichle S, Ferrand C, et al. Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for
blastic plasmacytoid dendritic cell leukemia
diagnosis. Cytom A. 2012;81(8):718-724. 21. Vermi W, Facchetti F, Rosati S, et al. Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-pro- ducing cells associated with myeloid disor- ders. Am J Surg Pathol. 2004; 28(5):585-595. 22.Rickmann M, Krauter J, Stamer K, et al. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. 2011;
90(9):1047-1058.
23. Mohty M, Jarrossay D, Lafage-Pochitaloff
M, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 2001;98(13):3750-3756.
24.Lucas N, Duchmann M, Rameau P, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019;33(10):2466-2480.
25. Viailly P-J, Mareschal S, Bertrand P, et al. GenerateReports: an Ion Torrent plugin summarizing a whole NGS experiment for clinical interpretation. 2015.
26. Wang W, Khoury JD, Miranda RN, et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid den- dritic cells permits establishment of a 10- color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021 Apr 1;106(4):1047- 1055.
27. Xiao W, Goldberg AD, Famulare CA, et al. Loss of plasmacytoid dendritic cell differen- tiation is highly predictive for post-induc- tion measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica. 2019;104(7):1378-1387.
28. Comeau MR, Van der Vuurst de Vries A-R, Maliszewski CR, Galibert L. CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion? J Immunol. 1950 2002;169(1):75-83.
29. MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DNJ. Characterization of human blood dendritic cell subsets. Blood. 2002;100(13):4512-4520.
30. Feuillard J, Jacob M-C, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002; 99(5):1556-1563.
31. Garnache-Ottou F, Vidal C, Biichlé S, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv. 2019;3(24):4238-4251.
32. Julia F, Dalle S, Duru G, et al. Blastic plasma- cytoid dendritic cell neoplasms: clinico- immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38(5):673-680.
33. Lamar E, Roggy A, Le Calvez G, et al. Blastic plasmacytoid dendritic cell neoplasm: report of a case with atypical cytology and immunophenotype. J Blood Disord. 2015;2(3):1033.
34. Martín-Martín L, Almeida J, Hernández- Campo PM, Sánchez ML, Lécrevisse Q, Orfao A. Immunophenotypical, morpholog- ic, and functional characterization of matu- ration-associated plasmacytoid dendritic cell subsets in normal adult human bone mar-
row. Transfusion. 2009; 49(8):1692-1708. 35. Martín-Martín L, López A, Vidriales B, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget.
2015;6(22):19204-19216.
36. Tsagarakis NJ, Kentrou NA, Papadimitriou
KA, et al. Acute lymphoplasmacytoid den- dritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010;34(4):438-446.
37. Mani R, Goswami S, Gopalakrishnan B, et al. The interleukin-3 receptor CD123 target- ed SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syn- drome patients and healthy donors. Haematologica. 2018;103(8):1288-1297.
38.Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848-858.
39. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138-3148.
40. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendrit- ic-cell neoplasm. N Engl J Med. 2019; 380(17):1628-1637.
41. Villani A-C, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017; 356(6335):eaah4573.
42. Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clini- co-pathologic and genetic features. Leukemia. 2016;30(11):2282.
43. Roumier C, Eclache V, Imbert M, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d’Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). Blood. 2003; 101(4):1277-1283.
44. Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recur- rent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-829.
45. Antony-Debré I, Duployez N, Bucci M, et al. Somatic mutations associated with leukemic progression of familial platelet dis- order with predisposition to acute myeloid leukemia. Leukemia. 2016; 30(4):999-1002.
46. Morita K, Suzuki K, Maeda S, et al. Genetic regulation of the RUNX transcription factor family has antitumor effects. J Clin Invest. 2017;127(7):2815-2828.
47.Kubota S, Tokunaga K, Umezu T, et al. Lineage-specific RUNX2 super-enhancer activates MYC and promotes the develop- ment of blastic plasmacytoid dendritic cell neoplasm. Nat Commun. 2019;10(1):1653.
48.Chopin M, Preston SP, Lun ATL, et al. RUNX2 mediates plasmacytoid dendritic cell egress from the bone marrow and con- trols viral immunity. Cell Rep. 2016; 15(4):866-878.
3066
haematologica | 2021; 106(12)